Creon pancrelipase: Phase III data

Data from a double-blind, crossover Phase III trial in 32 patients showed that Creon met the primary endpoint of significantly greater CFA vs. placebo (88.6% vs. 49.6%, p<0.001). Creon also met the secondary endpoint of significantly greater CNA vs. placebo (85.1% vs. 49.9%, p<0.001). There were fewer treatment-emergent adverse events reported with Creon compared with placebo. Data were published in the Journal of Cystic Fibrosis. ...